Loading...
XNAS
CVAC
, Last price  
USD
Name

CureVac NV

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
0.72
Div Yield, %
—
Shrs. gr., 5y
3.80%
Rev. gr., 5y
98.39%
Revenues
535m
+895.54%
12,871,00017,416,00048,900,000102,990,00067,420,00053,758,000535,180,000
Net income
162m
P
-71,241,000-99,873,000-129,074,000-411,716,000-249,029,000-260,167,000162,186,000
CFO
102m
P
-74,110,000-86,963,000522,403,000-733,128,000-286,177,000-267,887,000101,851,000

Profile

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
URL
https://www.curevac.com/
IPO date
Aug 14, 2020
Employees
904
Domiciled in
DE
Incorporated in
NL

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
535,180
895.54%
53,758
-20.26%
67,420
-34.54%
Cost of revenue
332,961
316,523
335,954
Unusual Expense (Income)
NOPBT
202,219
(262,765)
(268,534)
NOPBT Margin
37.79%
Operating Taxes
28,695
198
(126)
Tax Rate
14.19%
NOPAT
173,524
(262,963)
(268,408)
Net income
162,186
-162.34%
(260,167)
4.47%
(249,029)
-39.51%
Dividends
Dividend yield
Proceeds from repurchase of equity
236,086
66,484
BB yield
Debt
Debt current
5,321
5,005
4,980
Long-term debt
72,609
78,643
79,192
Deferred revenue
48,100
72,549
Other long-term liabilities
61,339
Net debt
(407,440)
(321,461)
(416,112)
Cash flow
Cash from operating activities
101,851
(267,887)
(286,177)
CAPEX
(14,315)
(52,320)
(93,222)
Cash from investing activities
(18,444)
(55,200)
(93,499)
Cash from financing activities
(5,114)
230,893
63,173
FCF
207,497
(299,886)
(309,717)
Balance
Cash
485,370
405,113
500,284
Long term investments
(4)
Excess cash
458,611
402,421
496,913
Stockholders' equity
696,608
516,941
534,734
Invested Capital
276,962
204,444
210,780
ROIC
72.09%
ROCE
27.48%
EV
Common stock shares outstanding
225,270
220,833
189,075
Price
Market cap
EV
EBITDA
221,028
(239,379)
(244,793)
EV/EBITDA
Interest
2,493
3,707
Interest/NOPBT